Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review
Qinghua Li, Engels Obi, Anne Marciniak, Rebecca Newman, Isabelle Whittle, Jason Kufakwaro · 2024
Read Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review by Qinghua Li, Engels Obi, Anne Marciniak, Rebecca Newman, Isabelle Whittle, Jason Kufakwaro (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11688082.txt.
Description
Qinghua Li and co-authors review care for a hard gut infection in a 2024 paper. The infection, from the germ Clostridioides difficile, hits about half a million people a year in the United States. Four cures face off: fidaxomicin, vancomycin, metronidazole, and stool transplant. Guides back fidaxomicin first, yet cost questions stay open. The team swept four data banks for studies from 2012 to 2022.
They kept 79 papers, then set a strict bar for fair outcome checks. Cure that held at one and two months ran high on fidaxomicin, up to about three in four patients. Rates on vancomycin ran low by the same marks. Return of the illness also trended low on fidaxomicin, though ranges touched. Cost studies found the drug good value in most checks, with gains from fewer hospital stays. Data on the other two cures stayed thin.
Catalog record
| CREATOR | Qinghua Li, Engels Obi, Anne Marciniak, Rebecca Newman, Isabelle Whittle, Jason Kufakwaro |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |